Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Sun-Young | - |
dc.contributor.author | Kim, Myo-Song | - |
dc.contributor.author | Kim, Min-Chul | - |
dc.contributor.author | Choi, Seong-Ho | - |
dc.contributor.author | Chung, Jin-Won | - |
dc.contributor.author | Choi, Sang Tae | - |
dc.date.accessioned | 2021-08-19T04:40:23Z | - |
dc.date.available | 2021-08-19T04:40:23Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1198-743X | - |
dc.identifier.issn | 1469-0691 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/48719 | - |
dc.description.abstract | Objectives: Early in vitro studies have suggested that hydroxychloroquine (HCQ) is a potentially useful drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. This study was conducted to determine whether HCQ had a preventive effect on coronavirus disease 2019 (COVID-19) in rheumatic disease patients who were taking HCQ. Methods: We conducted a population-based retrospective cohort study using the records of the Korean Health Insurance Review and Assessment (HIRA) claim records. The clinical data of patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) who were tested for SARS-CoV-2 were investigated. We compared the attack rate of COVID-19 between those who underwent HCQ therapy within 14 days before the test for SARS-CoV-2 (HCQ users) and HCQ non-users. Data were analysed using logistic regression models, χ2, and Student's t-tests. Results: As of 15th May 2020, 2066 patients with RA or SLE were tested for COVID-19. Among them, 31.4% (649/2066) were treated with HCQ. Most HCQ users (93.7%, 608/649) were taking 200–400 mg/day recommended for the treatment of rheumatic diseases. The attack rate of COVID-19 in the HCQ users (2.3%, 15/649) did not differ from that in the HCQ non-users (2.2%, 31/1417) (p 0.86). Conclusions: HCQ prophylactic use at a usual dose did not prevent COVID-19 in patients with rheumatic disease. © 2020 The Authors | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier B.V. | - |
dc.title | Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.cmi.2020.12.003 | - |
dc.identifier.bibliographicCitation | Clinical Microbiology and Infection, v.27, no.4, pp 611 - 617 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000659131600018 | - |
dc.identifier.scopusid | 2-s2.0-85098643855 | - |
dc.citation.endPage | 617 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 611 | - |
dc.citation.title | Clinical Microbiology and Infection | - |
dc.citation.volume | 27 | - |
dc.type.docType | Article; Early Access | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Hydroxychloroquine | - |
dc.subject.keywordAuthor | Pre-exposure prophylaxis | - |
dc.subject.keywordAuthor | Rheumatic diseases | - |
dc.subject.keywordAuthor | Severe acute respiratory syndrome coronavirus 2 | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.